Last reviewed · How we verify
Drug: CD07805/47 gel
CD07805/47 gel is a topical retinoid that promotes skin cell turnover and collagen remodeling to improve signs of photoaging and wrinkles.
CD07805/47 gel is a topical retinoid that promotes skin cell turnover and collagen remodeling to improve signs of photoaging and wrinkles. Used for Photoaged skin and facial wrinkles.
At a glance
| Generic name | Drug: CD07805/47 gel |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Retinoid |
| Target | Retinoid receptors (RAR/RXR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a retinoid compound formulated as a gel, CD07805/47 works by binding to retinoid receptors in skin cells, stimulating cellular differentiation and increasing collagen synthesis. This mechanism helps reduce fine lines, improve skin texture, and address photodamaged skin through enhanced dermal remodeling and increased cell turnover.
Approved indications
- Photoaged skin and facial wrinkles
Common side effects
- Skin irritation
- Erythema
- Dryness
- Peeling
Key clinical trials
- MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (PHASE4)
- Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Drug: CD07805/47 gel CI brief — competitive landscape report
- Drug: CD07805/47 gel updates RSS · CI watch RSS
- Galderma R&D portfolio CI